Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

On November 9, 2026 Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, reported financial results for the third quarter ended September 30, 2026 and provided a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need," said Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer of Bicara Therapeutics. "Achieving substantial enrollment in the FORTIFI-HN01 pivotal trial reflects strong execution by our team and growing recognition among investigators that HPV-negative disease requires a targeted approach grounded in its distinct biology. As we advance toward our planned interim analysis, our focus is twofold: moving with speed and aiming for ficerafusp alfa to enter the market with a competitive profile that gives physicians, patients, and payers a clear reason to choose it. At the same time, we are evaluating less-frequent dosing through FORTIFI-FLEX, which has the potential to further enhance ficerafusp alfa’s profile. With our commercial leadership team now in place, we are well-positioned as we continue to prepare to bring ficerafusp alfa to patients."

Third Quarter 2026 Highlights and Recent Progress

Ficerafusp Alfa in 1L R/M HPV-Negative HNSCC

Achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in first-line (1L) recurrent or metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), to enable topline results from an interim analysis in mid-2027.
Continue to enroll FORTIFI-FLEX, a randomized, open-label clinical trial that is evaluating ficerafusp alfa, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W) as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab. The company expects to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.
Key Anticipated Upcoming Milestones

HNSCC

Expect topline results from an interim analysis of the FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC in mid-2027.
Other Solid Tumors and Translational Data

Present data from Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ mCRC (RAS/BRAF wild type MSS) in January 2027.
Present preclinical data evaluating the effect of tumor-targeted TGF-β neutralization with ficerafusp alfa on fibrosis and drug penetration at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Immuno-Oncology & Advanced Therapies Congress 2026, taking place December 14-16 in London, United Kingdom.
Third Quarter 2026 Financial Results

Cash, Cash Equivalents and Marketable Securities: As of September 30, 2026, Bicara had cash, cash equivalents and marketable securities of $442.3 million, compared to $414.8 million in cash, cash equivalents and marketable securities as of December 31, 2025. Based on its current operating and development plans, the company expects that its existing cash, cash equivalents and marketable securities will fund operations into the first half of 2029.
Research and Development Expenses: Research and development expenses were $56.5 million for the third quarter of 2026 as compared to $33.0 million for the third quarter of 2025. The increase was primarily due to costs associated with the ongoing FORTIFI-HN01 pivotal trial, FORTIFI-FLEX trial, Phase 1/1b dose expansion cohorts, and an increase in personnel costs.
General and Administrative Expenses: General and administrative expenses were $19.2 million for the third quarter of 2026 as compared to $7.7 million for the third quarter of 2025. The increase was primarily due to additional personnel costs and professional fees associated with expanding the organization as the company advances its pivotal trial and prepares for potential commercialization.
Net Loss: Net loss totaled $71.2 million for the third quarter of 2026 compared to $36.3 million for the third quarter of 2025.
Upcoming Investor Conferences

Bicara will participate in the following upcoming investor conferences:

Stifel Healthcare Conference 2026 on November 11 at 9:20 a.m. ET
Jefferies Global Healthcare Conference on November 16 at 12:00 p.m. GMT
Piper Sandler 38th Annual Healthcare Conference on December 2 at 8:30 a.m. ET
Live webcasts of the fireside chats will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. Replays of the webcasts will be archived and available for 30 days following each event.

Conference Call Information
Bicara will host a live conference call and webcast at 8:30 a.m. ET today to discuss third quarter 2026 financial results and business updates. Individuals may register for the conference call by clicking the link here. Once registered, participants will receive dial-in details and a unique PIN that will allow them to access the call. An audio webcast will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. An archived replay will also be available for 30 days following the event.

(Press release, Bicara Therapeutics, NOV 9, 2026, View Source [SID1234674525])

Epitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer

On November 9, 2026 Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, reported that the first patient has been successfully dosed in OVACT, its first-in-human Phase 1/1b clinical trial evaluating its lead program, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

OVACT is a Phase 1/1b dose escalation trial designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype advanced HGSOC patients. Up to 30 women will be enrolled into the trial across up to 10 leading clinical centres in the UK.

HGSOC remains one of the most difficult-to-treat solid tumors, with around 80% of patients presenting with advanced or metastatic disease. While most women respond to first-line platinum chemotherapy, nearly all ultimately relapse and progress to platinum-resistant disease. Existing maintenance options are only effective in half of the ovarian cancer population and leave a major therapeutic gap among HRP+/BRCA-wildtype patients.

Dr. Klaus Edvardsen, MD, PhD, Chief Medical Officer of Epitopea, commented, "HGSOC is the most common and aggressive subtype of ovarian cancer. Treating the first patient with CryptiVax-1001 in our OVACT Phase 1/1b trial for HGSOC is a major milestone for Epitopea. Epitopea’s approach targets a novel repertoire of tumor-specific antigens that have been selected to provide broader patient benefit. We are motivated by the potential to provide meaningful durable treatment options for this underserved patient population."

Professor Susana Banerjee (MBBS MA PhD FRCP), the Chief Investigator of Epitopea’s OVACT trial, Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust and Professor in Women’s Cancers at The Institute of Cancer Research, London, said, "It is exciting to offer patients the option of the OVACT trial and I am delighted that we are underway with the first patient treated. The CryptiVax-1001 vaccine has the potential to meaningfully extend remission for women where currently available maintenance therapies deliver limited durable benefit."

(Press release, Epitopea, NOV 9, 2026, View Source [SID1234674470])

Rakovina Therapeutics Announces Shares for Debt Transaction

On November 9, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported that it has entered into agreements to settle an aggregate of $235,908.60 in outstanding obligations through the issuance of common shares of the Company (the "Settlement Shares") at a deemed price of $0.175 per share, based on the closing price of the Company’s common shares on November 4, 2026 (the "Debt Settlement").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Debt Settlement comprises $125,493.70 in accrued interest owing to holders of the Company’s existing 12.0% unsecured convertible debentures and $110,414.90 in outstanding amounts payable to certain service providers.

The issuance of the Settlement Shares remains subject to all requisite regulatory approvals, including approval of the TSX Venture Exchange (the "TSXV"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.

Stock Option Grant

The Company also announces that its board of directors has approved the grant of an aggregate of 124,000 stock options (the "Options") to certain directors and consultants pursuant to the Company’s Long-Term Incentive Plan.

The Options have an exercise price of $0.20 per common share, expire five years from the date of grant and vest in equal quarterly instalments over a one-year period.

(Press release, Rakovina Therapeutics, NOV 9, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-shares-for-debt-transaction [SID1234674486])

Biond Biologics Doses First Patient with BND-67, a First-in-Class Anti-CD28 Shedding Antibody Designed to Drive Anti-Tumor Immunity

On November 9, 2026 Biond Biologics Ltd. ("Biond" or the "Company"), a private clinical-stage biopharmaceutical company developing first-in-class immunotherapies for cancer and immune-mediated diseases, reported that the first patient has been dosed in a first-in-human Phase 1 dose escalation clinical trial in advanced solid tumors evaluating BND-67, a novel antibody-based therapy designed to prevent CD28 shedding.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first patient was treated at the Institute of Oncology, Davidoff Center, Rabin Medical Center, Israel, one of multiple clinical sites participating in the study. The trial aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BND-67. The unique clinical design includes a lead-in BND-67 monotherapy treatment followed by combination therapy of BND-67 and anti-PD-1 therapy, in patients relapsing on anti-PD-1 therapy following prior clinical benefit, across selected oncology indications. The first patient completed BND-67 0.3 mg/kg monotherapy without any dose-limiting toxicities or infusion-related reactions and is now receiving BND-67 in combination with nivolumab once every two weeks (MOH_2026-04-14-015766).

"Patients who relapse after responding to immunotherapy represent a significant unmet medical need. BND-67 is based on a compelling biological rationale and targets a previously unexplored mechanism of immune dysfunction like CD28 shedding," said Professor Salomon Stemmer, M.D., Head of Research, Development and Innovation and Deputy Director of Davidoff Center at the Rabin Medical Center, Israel, and a clinical investigator in the trial. "We are pleased to participate in this first-in-human study and investigate its potential to improve outcomes for patients with advanced solid tumors."

"BND-67 opens an entirely new therapeutic avenue for cancer immunotherapy," said Giovanni Selvaggi, MD, Chief Medical Officer at Biond. "CD28 has long been viewed as a cornerstone for T-cell activation, yet no targeted therapy has successfully harnessed it without compromising safety. By preventing CD28 shedding, BND-67 is designed to preserve physiological CD28 signaling and potentiate anti-tumor immune response, without the systemic toxicity associated with CD28 agonism. The BND-67 0.3 mg/kg was shown to be safe and tolerable with sustained receptor occupancy." The Phase 1 lead-in design is intended to establish BND-67’s initial safety and tolerability profile while assessing early signals of clinical activity.

About BND-67 and CD28 Shedding

BND-67 is a first-in-class immunotherapy designed to inhibit pathological CD28 shedding, an immune evasion mechanism found across many types of cancers first described by Biond. CD28 is a critical co-stimulatory receptor required for effective T-cell activation, proliferation, and persistence. In cancer patients, CD28 can be cleaved from the surface of T cells, by specific matrix metalloproteases (MMPs) that are secreted from various cells including T cells and from the cancer cells, leading to impaired immune responses and reduced sensitivity to immunotherapies.

By preventing CD28 shedding, BND-67 is designed to enhance T-cell activation and expansion while selectively inhibiting regulatory T-cell differentiation and suppressive activity. Preclinical studies have demonstrated that BND-67 induces a potent and sustained anti-tumor immune response, both as a monotherapy and in combination with T-cell activating therapies including PD-1 inhibitors and T-cell engagers while demonstrating a favorable safety profile in animal models.

(Press release, Biond Biologics, NOV 9, 2026, View Source [SID1234674509])

Tango Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights

On November 9, 2026 Tango Therapeutics, Inc. (NASDAQ: TNGX) a clinical-stage biotechnology company committed to delivering breakthrough targeted therapies that extend and improve the lives of patients with cancer, reported financial results for the third quarter ended September 30, 2026, and provided business highlights.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In 2026, Tango has made significant strides towards bringing vopimetostat to patients with pancreatic cancer," said Malte Peters, MD, President and Chief Executive Officer of Tango. "This progress is rooted first in the data. Last month at ESMO (Free ESMO Whitepaper), we shared promising data from the combination of vopimetostat plus daraxonrasib that reinforced the potential of this program to raise the bar for patients with MTAP-deleted and RAS-mutant pancreatic cancer. Based on those data, we have engaged with the FDA on our plans for a registrational study in the front-line setting and plan to initiate that study in the first half of next year. In addition, we plan to engage with regulators on the possibility of seeking accelerated approval of this combination in second line pancreatic cancer. Beyond pancreatic cancer, we look forward to sharing our strategy in lung cancer, supported by data from vopimetostat and TNG456, in January of next year. I am grateful to the dedicated Tango team for the progress we have made in 2026 thus far and look forward to advancing our mission of bringing these important therapies to patients with cancer."

Clinical Pipeline Updates

ESMO DATA. In October 2026, Tango reported promising updated data from vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors daraxonrasib or zoldonrasib in patients with MTAP-deleted, RAS-mutant pancreatic cancer. Data demonstrated that vopimetostat in combination with daraxonrasib achieved an 82% objective response rate (ORR) and 88% nine-month progression-free survival (PFS) rate in efficacy-evaluable patients with second and third line pancreatic ductal adenocarcinoma (PDAC), and median PFS was not yet reached. Efficacy-evaluable patients are those patients who received their first dose of treatment at least 14 weeks prior to the data cutoff date of August 20, 2026. As of the data cutoff date, the combination had a generally well-tolerated safety profile at dose level one (vopimetostat 200 mg/daraxonrasib 100 mg QD).

PIVOTAL STUDY PLANS. Based upon the encouraging Phase 1/2 data and discussions with the US Food and Drug Administration (FDA), Tango intends to initiate a pivotal Phase 3 study of the combination of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer. The Company anticipates that this will be a global, randomized study of vopimetostat 200 mg plus daraxonrasib 100 mg, once-daily vs. standard-of-care chemotherapy. The planned study has dual primary endpoints of ORR and PFS, with overall survival as a key secondary endpoint. The Company plans to initiate the study in the first half of 2027. In addition, Tango intends to discuss the possibility of pursuing approval of this combination in patients with second line PDAC with regulatory authorities.

ERASCA STUDY START. In November 2026, the Company announced that the Phase 1/2 study of oral PRMT5 inhibitor vopimetostat in combination with pan-RAS molecular glue ERAS-0015 in patients with MTAP-deleted PDAC and MTAP-deleted/RAS-mutant non-small cell lung cancer (NSCLC) has initiated enrollment.

LEADERS IN PRMT5 INHIBITION. In October 2026, the Company announced that it plans to initiate a Phase 1/2 combination study of vopimetostat plus panRAS inhibitors in patients with MTAP-wild type pancreatic cancer in the first half of 2027. This study of approximately 25 patients will explore the Company’s hypothesis, based on a strong biological rationale and emerging clinical and preclinical data, that the synergy observed in MTAP-deleted cancers has the potential to extend to MTAP-wild type cancers.

Corporate Updates

FOCUS ON PRMT5. In October 2026, Tango disclosed a strategic reprioritization of the Company’s research and development activities to focus on the advancement of PRMT5-targeted therapies.

Upcoming Expected Milestones

Disclose vopimetostat lung cancer monotherapy data in January 2027
Disclose TNG456 data in lung cancer, glioblastoma and other cancers in January 2027
Initiate a Phase 3 randomized-controlled trial of vopimetostat plus daraxonrasib in front-line MTAP-deleted pancreatic cancer in 1H 2027
Initiate Phase 1/2 vopimetostat plus panRAS inhibitor study in MTAP-wild type pancreatic cancer in 1H 2027

Financial Results

As of September 30, 2026, the Company held $977.5 million in cash, cash equivalents and marketable securities, which the Company expects to fund its current operating plan.

Collaboration revenue was $0 for the three months ended September 30, 2026, compared to $53.8 million for the same period in 2025, and $0 for the nine months ended September 30, 2026, compared to $62.4 million for the same period in 2025. All remaining deferred revenue from the upfront and research option-extension payments under the Gilead collaboration was recognized as collaboration revenue during the year ended December 31, 2025 as a result of the truncation of the collaboration agreement which concluded all research activities in August 2025.

Research and development expenses were $48.9 million for the three months ended September 30, 2026, compared to $30.8 million for the same period in 2025, and $119.7 million for the nine months ended September 30, 2026, compared to $100.1 million for the same period in 2025. The change was primarily due to increased spend related to the advancement of the vopimetostat and TNG456 clinical programs. This increase was partially offset by decreased spend due to the Company’s portfolio prioritization efforts.

General and administrative expenses were $29.2 million for the three months ended September 30, 2026, compared to $8.9 million for the same period in 2025, and $67.0 million for the nine months ended September 30, 2026, compared to $31.7 million for the same period in 2025. The increase was primarily due to increased spend on personnel-related costs, including share-based compensation expense which included increases derived from the modification of previously issued equity awards for former executive officers.

Net loss for the three months ended September 30, 2026 was $68.4 million, or $0.39 per share (basic and diluted), compared to a net income of $15.9 million, or $0.14 per share (basic) and $0.13 per share (diluted), in the same period in 2025. Net loss for the nine months ended September 30, 2026 was $169.2 million, or $1.08 per share (basic and diluted), compared to a net loss of $62.8 million, or $0.57 per share (basic and diluted), in the same period in 2025.

(Press release, Tango Therapeutics, NOV 9, 2026, View Source [SID1234674526])